retatrutide clinical trial data Eli Lilly's Phase 3 Results: 28.7% Weight Loss Retatrutide hits 28.3% weight loss

Unlike AAV vectors, which provoke immunological responses after the second administration, LNPs are expected to allow repeated administrations 37,38

Key takeaways GLP-1 agonists are FDA-approved drugs for Type 2 diabetes or weight management

As one of the first small-molecule oral GLP-1 therapies, orforglipron offers significant advantages in manufacturing and scalability, opening access to broader populations

Retatrutide slows gastric emptying, meaning alcohol remains in the digestive system longer and produces more pronounced effects

Some clients also choose to incorporate Emsculpt NEO for additional muscle support during their weight loss journey

But the weight loss comes almost entirely from the input side of the energy balance equation: less food in